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Edited by Lukas HuberAbstract The peptide hormone somatostatin, as well as the
somatostatin analog octreotide, induces rapid morphological
changes in neuroendocrine cells. The eﬀect can be detected in less
than 2 min: retraction ﬁbers are formed, cells round up and
cell–cell contacts are broken. Somatostatin-dependent cell con-
traction is inhibited by Y-27632, indicating that this eﬀect is
dependent on Rho kinase. In BON1 cells, the somatostatin-
induced inhibition of forskolin-induced secretion of chromogra-
nin A is not blocked by Y-27632. It is therefore concluded that
the inhibitory eﬀect of somatostatin in forskolin-stimulated cells
is not dependent on cell contraction.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Somatostatin is a tetra–deca peptide hormone, ﬁrst isolated
from sheep hypothalamic cells and known to be a potent inhib-
itor of peptide hormone secretion. Subsequently, other func-
tions such as inhibition of cell growth and inhibition of
exocrine pancreatic secretion have been described. Somato-
statin acts through speciﬁc membrane bound receptors belong-
ing to the seven-transmembrane receptor superfamily and until
today ﬁve diﬀerent receptor subtypes have been identiﬁed [1].
Because of its potent inhibitory eﬀect on hormone secretion,
somatostatin was early proposed to be used in clinical disor-
ders related to excessive hormone secretion. In 1977, the ﬁrst
report of the success of such treatment was published [2]. How-
ever, the short half-life of the natural hormone made it diﬃcult
to use except in selected cases. In 1982 the ﬁrst long-acting ana-
log, octreotide, was presented and this compound has been
widely used in the clinic [3].
Today somatostatin analogs are used to treat various disor-
ders connected to hypersecretion of hormones such as acrom-
egali and various neuroendocrine tumors. The aim of this
treatment is mainly to reduce the symptoms induced by this
excessive hormone secretion, but other eﬀects such as growth
inhibition are also of interest [4].
Somatostatin-induced relaxation of smooth muscle has been
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doi:10.1016/j.febslet.2007.04.0197]. However, it has also been reported that somatostatin can
induce contraction of smooth muscle [5,8]. These conﬂicting
results are probably depending on the experimental set up.
Also, in experiments employing organisms and tissues, indirect
eﬀects may inﬂuence the results.
The present report is focused on detection of morphological
responses of somatostatin in neuroendocrine/hormone-pro-
ducing cells. The model system used is BON1 cells. This cell
line is derived from a metastasis of a human pancreatic neuro-
endocrine tumor [9]. BON1 cells produce and secrete high lev-
els of chromogranin A, a protein located in dense core vesicles.
Somatostatin-induced eﬀects in these cells, including inhibition
of chromogranin A secretion, have been reported previously
[10].
Here, we show that somatostatin induces a morphological
response in neuroendocrine cells. The cells contract rapidly
and the eﬀect is shown to be dependent on the Rho kinase.
Somatostatin-mediated inhibition of secretion from BON1
cells is not dependent on cell contraction; however, the con-
traction shows a negative correlation with secretion, suggesting
that these events are related. Furthermore, it is shown that
lysophosphatidic acid (LPA) is a co-stimulator of forskolin-in-
duced hormone secretion.2. Materials and methods
2.1. Cell cultivation
Human neuroendocrine pancreatic tumour cells, BON1, were culti-
vated in 50% Dulbecco’s modiﬁed Eagle’s medium and 50% F12 sup-
plemented with 10% foetal bovine serum (FBS) and penicillin/
streptomycin. Human neuroblastoma cells IMR-32 was cultivated in
Eagles modiﬁed essential medium supplemented with 10% FBS, 1%
non-essential amino acids and penicillin/streptomycin. All cells were
cultivated at 37 C in an atmosphere containing 5% CO2.
2.2. Cell stimulations and ﬂuorescence microscopy
Cells were seeded in chamber slides and cultivated for 48 h. Prior to
stimulation, the cells were incubated in medium devoid of FBS over
night. Stimulation with somatostatin-14 (Sigma), Octreotide (Novar-
tis), L-A-lysophosphatidic acid (LPA, Sigma), Y-27632 (Sigma) and
forskolin (Sigma) were performed as indicated in the ﬁgure legends.
After stimulation, the chamber slides were ﬁxed in 3.8% formaldehyde
in phosphate-buﬀered saline (PBS) for 30 min at 25 C and washed in
PBS. The cells were permeabilized in 0.2% Triton X-100 in PBS for
5 min and washed in PBS. Blocking was done using 5% FBS in PBS
for 1 h at 25 C. Cells were then incubated with a rabbit antibody di-
rected against chromogranin A [19] in 5% FCS in PBS for 1 h at 25 C
and washed again in PBS. Incubation with FITC-labeled secondary
anti-rabbit antibody (DAKO) and TRITC-labeled phalloidin (Sigma)
in 5% FCS in PBS was performed for 1 h at 25 C and subsequently
the cells were washed in PBS. The slides were mounted with cover-
slips by the use of Vectashield (Vector Laboratories). Cells were
photographed by an Axiocam HRm camera employing the Axiovisionblished by Elsevier B.V. All rights reserved.
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Axioplan2 microscope.
2.3. Time lapse studies of living cells
Cells were seeded in chamber slides and cultivated for 48 h. Prior to
stimulation with somatostatin, the cells were incubated in medium de-
void of FBS over night. Time lapse series of images were started before
stimulation and images were recovered every 10th second using a
Canon Powershot digital camera employing the Remote Capture
imaging software and a Axiovert 25 microscope (Zeiss) equipped with
a phase contrast 40· objective.
2.4. Chromogranin A secretion assay
Conﬂuent BON1 cells in 24 well plates were washed with serum-
free medium and thereafter stimulated with somatostatin, forskolin,
LPA and Y-27632 for 60 min as indicated in the ﬁgure legends. The
conditioned medium was then aspirated, centrifuged and subjected
to a chromogranin A radioimmuno assay (EuroDiagnostica). All
experiments were performed in triplicates and repeated at least three
times. Variations between samples in an experiment were less than
10%.Fig. 1. BON1 cells were stimulated with 500 nM somatostatin, 100 nM for
thereafter ﬁxed and stained with ﬂuorescent phalloidin in order to visualize3. Results
3.1. Somatostatin induces rapid rearrangement of the actin
ﬁlament system
The eﬀect of somatostatin treatment on neuroendocrine cell
morphology was examined using BON1 cells. These cells are
derived from a metastasis of a neuroendocrine pancreatic tu-
mor [9]. Previous studies, based on northern blot analysis, have
identiﬁed mRNA for somatostatin receptors 1, 2 and 5 in
BON1 cells [10]. In contrast, by using real time polymerase
chain reaction, we can detect the expression of all ﬁve somato-
statin receptors in BON1 cells (data not shown). In our exper-
iments, the expression level of receptor subtype 4 is very low
and it is currently unclear whether BON1 cells should be re-
garded as somatostatin receptor 4 positive. We have previously
shown that somatostatin, as well as synthetic somatostatin
analogs, induce responses in this cell line [10]. Using ﬂuores-
cently labeled phalloidin, the actin cytoskeleton was visualized.skolin and 10 lM Y-27632, as indicated in the ﬁgure, for 10 min and
the actin ﬁlament system. Scale bar represents 50 lm.
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numerous thin ﬁlopodia-like protrusions in a majority of the
cells (Fig. 1, upper panel).
Time course studies revealed that the protrusions are actu-
ally formed very fast and appear after less than 2 min, peaks
at 10 min and is virtually absent after 60 min (data not shown),
indicating that this is a rapid and transient somatostatin-med-
iated response.
Octreotide is a long lived and potent somatostatin-analog
used in clinical situations where a reduction of hormone circu-
lation is wanted. In BON1 cells, Octreotide had similar eﬀects
on the actin cytoskeleton as somatostatin (Fig. 2).
3.2. Morphological eﬀects detected in living cells
Next, we performed time lapse studies on living cells using
phase contrast microscopy. An image was captured every
10th second. In these experiments it was clear that the mainFig. 2. BON1 cells were stimulated with 1 lM somatostatin or 1 lM
octreotide for 10 min and thereafter ﬁxed and stained with ﬂuorescent
phalloidin in order to visualize the actin ﬁlament system. Scale bar
represents 50 lm.morphological eﬀect of somatostatin in BON1 cells is actually
cell contraction. The cells retract, round up, cell–cell contacts
are broken and membrane blebs are formed (Fig. 3). In
Fig. 3, it is possible to detect the contraction of individual cells
loosing contact with other cells and cell–surface contact, while
in the ‘‘ﬁlm-like’’ sequence of images in Supplementary mate-
rial 1 it is clear that most of the cells contract. This phenome-
non can be detected at 10 nM somatostatin but is stronger at
higher concentrations. Thus, the ﬁlopodia-like structures seen
in phalloidin-labeled ﬁxed cells are not active protrusions but
rather retraction ﬁbers. This ﬁnding explains the extremely ra-
pid formation of actin-containing ‘‘protrusions’’ seen in ﬁxed
cells.
The rapid morphological eﬀects of somatostatin on hor-
mone-producing cells are not restricted to BON1 cells; con-
traction and retraction was seen also in the human
neuroblastoma cell lines IMR-32 (Fig. 4), SKNAS and Kelly
cells (not shown). Thus, this eﬀect of somatostatin is probably
present in various hormone-producing cells.Fig. 3. BON1 cells were stimulated with 500 nM somatostatin and the
morphological response was studied by phase contrast microscopy.
Images were captured every 10th second. Arrows indicate cells that
contract, loose adhesion and round up. Scale bar represents 50 lm. In
the ﬁlm-like sequence of Supplementary material 1, it is clear that most
cells contract in response to somatostatin.
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Activation of the Rho kinase (Rock) is tightly linked to cell
contraction. Rock phosphorylates myosin and myosin phos-
phatase, both events leading to the activation of myosin
[11,12]. The activated myosin contracts actin ﬁlaments leading
to cell contraction. BON1 cells treated with the low molecular
weight compound Y-27632, a speciﬁc inhibitor of Rock [13],
had similar morphology as unstimulated cells (Fig. 1, lower pa-
nel). When cells were stimulated with somatostatin in presence
of Y-27632 the contractive eﬀect was inhibited (Fig. 1, lower
panel), indicating that the somatostatin-mediated cell contrac-
tion is Rock-dependent. This interesting observation raises the
question whether Rock is involved also in the regulation of
secretion seen in neuroendocrine cells stimulated with somato-
statin.
3.4. Somatostatin induces a redistribution of chromogranin
A-containing vesicles
In order to visualize hormone-containing dense core vesicles,
BON1 cells were subjected to immunoﬂuorescence staining ofFig. 4. The morphological response of IMR-32 cells stimulated with
500 nM somatostatin was studied by phase contrast microscopy.
Images were captured every 10th second. Scale bar represents 50 lm.
The ﬁlm-like sequence of images in Supplementary material 2 covers
the process during 25 min. Note that IMR-32 cells grow in clusters-
containing several cells.chromogranin A. In Fig. 5, it is shown that a majority of the
dense core vesicles in unstimulated cells are located at the
periphery of the cells. When cells were stimulated with somato-
statin for 10 min, this pattern was altered and most chromogr-
anin A positive vesicles were found in the perinuclear region.
This response correlates well in time with the morphological
eﬀects and it is likely that the hormone-containing vesicles
are translocated to the perinuclear region as the cells round
up and retract protrusions.
3.5. Is there a connection between actin ﬁlament rearrangements
and hormone secretion?
Chromogranin A is good marker for exocytosis of dense
core vesicles of neuroendocrine cells [14,15]. Since FBS con-
tains chromogranin A, the experiments were performed in
serum-free conditions. The amount of chromogranin A in
the conditioned media was determined using a radio-immuno
assay. Upon stimulation with 1 lM somatostatin the secretion
of chomogranin A was decreased by approximately 20%.
When cells are incubated in serum-free conditions the level
of secretion of dense core vesicles is low. In order to study
BON1 cells in situations where the secretion is stimulated a
new forskolin-based assay was developed. Forskolin is a
strong inducer of regulated exocytosis [16]. In Fig. 6, it is
shown that forskolin enhances the secretion of chromogranin
A in BON1 cells. Furthermore, the somatostatin-mediated
inhibition was signiﬁcantly increased in forskolin-treated cells,Fig. 5. Somatostatin-induced translocation of chromogranin A-con-
taining vesicles was detected by immunoﬂuorscence microscopy.
BON1 cells, unstimulated (control) or stimulated for 10 min with
500 nM somatostatin were ﬁxed and subjected to immunoﬂuorescence
staining. Cells were visualized by TRITC-labeled (red) phalloidin and
chomogranin A was detected by an antibody directed against this
protein followed by a FITC-labeled (green) secondary anti-rabbit
antibody. Scale bar represents 50 lm.
Fig. 6. BON1 cells were stimulated with 100 nM forskolin together
with somatostatin at concentrations indicated in the ﬁgure. Secretion
of chromogranin A into the conditional media was determined. Level
of secretion is expressed as arbitrary units where the unstimulated
sample (no forskolin) is 1. Error bars represent two S.D.
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somatostatin on chromogranin A secretion could be detected
at 10 nM (Fig. 6) which is similar to the lower limit of detec-
tion of somatostatin-dependent cell contraction.
As most documented eﬀects of somatostatin are related to
regulation of secretion, we wanted to study the relation
between the somatostatin-induced cytoskeletal and secretory
eﬀects. The actin cytoskeleton of BON1 cells stimulated by
forskolin appeared as similar to untreated cells (Fig. 1, middle
panel). In presence of forskolin the somatostatin-induced con-
traction was totally absent. In the presence of Y-27632, the
secretion from unstimulated cells was reduced by 50%
(Fig. 7). This result suggests that Rock actually has a positive
eﬀect on exocytosis. However, forskolin could overcome the
Y-27632-related inhibition (Fig. 7). The inhibitory action of
somatostatin in forskolin stimulated cells was not signiﬁcantlyFig. 7. Conﬂuent BON1 cells were stimulated with 500 nM somatostatin (
combinations as indicated in the ﬁgure, for 1 h and the conditioned media was
is expressed as arbitrary units where the unstimulated sample is 1. Error baraltered by Y-27632. Therefore, it appears that inhibition of
secretion is not dependent on cell contraction.3.6. Lysophosphatidic acid is a co-stimulator of hormone
secretion
The small GTPase Rho and its eﬀector Rock are main acti-
vators of myosin/actin induced cell contraction [17]. Lysophos-
phatidic acid (LPA) is a well-known activator of Rho and
Rock acting via a G-protein coupled receptor (reviewed in
Ref. [18]). In order to determine if Rho/Rock have positive
eﬀects on secretion, BON1 cells were stimulated with LPA.
This compound alone had no detectable eﬀect on chromogra-
nin A secretion (Fig. 7). In the presence of forskolin, however,
LPA had a prominent stimulatory eﬀect on secretion.4. Discussion
We have shown that somatostatin can induce cell contrac-
tion in various hormone-producing cells. The response is de-
tected at similar concentrations as the inhibitory action of
somatostatin on secretion, indicating that somatostatin-in-
duced cell contraction has physiological relevance. That octre-
otide has similar eﬀects on cell morphology as somatostatin
indicates that further studies of this phenomenon are of clinical
importance. Also, the ﬁnding that chromogranin A-containing
vesicles are translocated from the cell periphery to the perinu-
clear region in response to somatostatin should be further
investigated. It is possible that somatostatin-induced inhibition
of secretion, in part, is dependent of the observed translocation
of secretory vesicles, as the vesicles after stimulation have less
contact with the plasma membrane. One should bear in mind
though that only a small fraction of the dense core vesicles in
an endocrine cell are mature (ready for exocytosis). From this
experiment it cannot be concluded that the mature secretory
vesicles have reduced contact with the plasma membrane after
somatostatin stimulation.
It is shown that the somatostatin-induced cell contraction is
dependent on Rock activity whereas inhibition of Rock cannot
inhibit somatostatin-induced inhibition of secretion.sst), 100 nM forskolin (for), 2 lM LPA and 10 lM Y-27632 (Y), in
subjected to a chromogranin A radio immune assay. Level of secretion
s represent two S.D.
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secretion suggests that the activation of this protein might pro-
mote exocytosis. This idea led to the ﬁnding that LPA can
function as a co-stimulator of regulated secretion in endocrine
cells, possibly through the activation of Rho/Rock. To our
knowledge, LPA has not previously been implicated in regula-
tion of secretion in neuroendocrine cells. Further studies of the
eﬀects of LPA on neuroendocrine cells are needed in order to
elucidate the involvement of this natural compound in the reg-
ulation of hormone secretion in vivo.
Forskolin and somatostatin have opposing eﬀects on both
secretion and morphology, suggesting that these events are
connected. Forskolin can inhibit somatostatin-mediated cell
contraction while somatostatin can inhibit forskolin-induced
secretion. The inhibition of forskolin-induced secretion by
somatostatin appears not to be dependent on cell contraction.
Our study does not support a model where cell contraction is
involved in the inhibitory eﬀects of somatostatin on secretion.
However, if rapid cell contraction is an immediate mechanism
for somatostatin-induced inhibition of secretion, such eﬀects
would not be detected in our secretory assays.
Further studies of cell contraction by somatostatin are
needed in order to increase the physiological understanding
of this hormone and its clinically used analogs.
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